Ricardo Restrepo-Jaramillo, MD
Pulmonary Disease · Tampa, FLNPI 1295994952
Payments from drug & device makers
Across 969 payments — averaging $3038.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1.4M
- United Therapeutics Corporation$1.1M
- Actelion Pharmaceuticals US, Inc.$144K
- Insmed, Inc.$144K
- Bayer$89K
- Novartis$30K
- plus $58K from 22 others
Across 8 payments — averaging $372.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 61 | $1,352,782 |
| United Therapeutics Corporation | 563 | $1,126,860 |
| Actelion Pharmaceuticals US, Inc. | 160 | $144,424 |
| Insmed, Inc. | 44 | $144,100 |
| Bayer | 63 | $88,701 |
| Novartis | 1 | $30,059 |
| Actelion Pharmaceuticals, Ltd | 8 | $28,810 |
| Janssen Research & Development, LLC | 6 | $15,500 |
| Liquidia Technologies, Inc. | 8 | $6,878 |
| Chiesi USA, Inc. | 5 | $4,063 |
| Abiomed | 4 | $438 |
| Boehringer Ingelheim | 8 | $434 |
| La Jolla Pharmaceutical Company | 4 | $364 |
| Astellas Pharma US Inc | 6 | $313 |
| Innovation Technologies Inc | 1 | $174 |
| Sandoz | 4 | $146 |
| Johnson & Johnson(2 entities) | 5 | $108 |
| ANI Pharmaceuticals, Inc. | 3 | $98 |
| Shionogi Inc | 3 | $57 |
| Vertex | 2 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $46 |
| Mylan Specialty L.p. | 2 | $43 |
| Mallinckrodt Hospital Products Inc. | 1 | $28 |
| Melinta Therapeutics, LLC | 1 | $25 |
| Gilead | 1 | $23 |
| Atricure, Inc. | 1 | $20 |
| Getinge USA Sales, LLC | 1 | $17 |
| Advanced Respiratory, Inc | 1 | $14 |
How this compares
$2,944,575 in reported general payments places this provider in the 95th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in Tampa
- Rafael MartinezTampa$917K
- Karel CaleroTampa$542K
- Mark RumbakTampa$528K
- Domenick ReinaTampa$469K
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.